RxDoctor Payments Data

Heather Nelson, NP

Nurse Practitioner · Charlotte, NCNPI 1699145722

Payments from drug & device makers

$1,647in general payments, 2019–2025

Across 19 payments — averaging $86.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$596
  • Teva Pharmaceuticals USA, Inc.$344
  • Biogen$107
  • Genentech, Inc.$103
  • Otsuka America Pharmaceutical, Inc.$103
  • Impel Pharmaceuticals Inc.$101
  • plus $292 from 4 others

What the payments were for

  • Food & beverage$1,647100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,647 in reported general payments places this provider in the 80th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$28,996
Medicare patients
87
Services billed
2,398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate50$85,148
QuliptaAtogepant45$65,578
Emgality PenGalcanezumab-Gnlm29$31,495
Ajovy AutoinjectorFremanezumab-Vfrm18$29,207
Aimovig AutoinjectorErenumab-Aooe27$27,908
UbrelvyUbrogepant19$27,159
Emgality SyringeGalcanezumab-Gnlm22$15,441
Memantine Hcl172$4,958
Donepezil Hcl229$4,398
RizatriptanRizatriptan Benzoate69$1,454
Naratriptan Hcl59$1,423
Sumatriptan Succinate25$801
Gabapentin22$563
Sertraline Hcl55$507
Topiramate31$485

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$596$92,73664 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →